These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32398466)

  • 1. Treatment of neurogenic lower urinary tract symptoms: main contributions from 2018 and 2019.
    Abreu-Mendes P; Cruz F; Martins-Silva C
    Curr Opin Urol; 2020 Jul; 30(4):486-490. PubMed ID: 32398466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower Urinary Tract Symptoms: What's New in Medical Treatment?
    Peyronnet B; Brucker BM; Michel MC
    Eur Urol Focus; 2018 Jan; 4(1):17-24. PubMed ID: 29665997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinational effects of muscarinic receptor inhibition and β3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury.
    Wada N; Shimizu T; Takai S; Shimizu N; Tyagi P; Kakizaki H; Yoshimura N
    Neurourol Urodyn; 2017 Apr; 36(4):1039-1045. PubMed ID: 27367752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron.
    Zachariou A; Filiponi M; Baltogiannis D; Giannakis J; Dimitriadis F; Tsounapi P; Takenaka A; Sofikitis N
    Can J Urol; 2017 Dec; 24(6):9107-9113. PubMed ID: 29260636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.
    Sebastianelli A; Russo GI; Kaplan SA; McVary KT; Moncada I; Gravas S; Chapple C; Morgia G; Serni S; Gacci M
    Int J Urol; 2018 Mar; 25(3):196-205. PubMed ID: 29205506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Life Data on Mirabegron in Neurogenic Bladder Dysfunction.
    Soebadi MA; Hakim L; Van der Aa F; De Ridder D
    Urol Int; 2019; 103(2):195-201. PubMed ID: 31096260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
    Oelke M; Bachmann A; Descazeaud A; Emberton M; Gravas S; Michel MC; N'dow J; Nordling J; de la Rosette JJ;
    Eur Urol; 2013 Jul; 64(1):118-40. PubMed ID: 23541338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms.
    Serati M; Andersson KE; Dmochowski R; Agrò EF; Heesakkers J; Iacovelli V; Novara G; Khullar V; Chapple C
    Eur Urol; 2019 Jan; 75(1):129-168. PubMed ID: 30293906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurogenic bladder: from diagnosis to management.
    Goldmark E; Niver B; Ginsberg DA
    Curr Urol Rep; 2014 Oct; 15(10):448. PubMed ID: 25118855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient.
    Makhani A; Thake M; Gibson W
    Clin Interv Aging; 2020; 15():575-581. PubMed ID: 32368024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Non-neurogenic Lower Urinary Tract Symptoms-A Review of Key Publications from 2018 Onward.
    Abreu-Mendes P; Martins-Silva C; Antunes-Lopes T; Cruz F
    Eur Urol Focus; 2021 Nov; 7(6):1438-1447. PubMed ID: 32624454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
    Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
    Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of pharmacotherapy for male patients with urgency and stress incontinence.
    Andersson KE
    Curr Opin Urol; 2014 Nov; 24(6):571-7. PubMed ID: 25144147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies in treating male lower urinary tract symptoms.
    Füllhase C; Soler R; Gratzke C
    Curr Opin Urol; 2014 Jan; 24(1):29-35. PubMed ID: 24285261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms.
    Sakalis VI; Karavitakis M; Bedretdinova D; Bach T; Bosch JLHR; Gacci M; Gratzke C; Herrmann TR; Madersbacher S; Mamoulakis C; Tikkinen KAO; Gravas S; Drake MJ
    Eur Urol; 2017 Nov; 72(5):757-769. PubMed ID: 28666669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
    Matsuo T; Miyata Y; Kakoki K; Yuzuriha M; Asai A; Ohba K; Sakai H
    BMC Urol; 2016 Jul; 16(1):45. PubMed ID: 27473059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirabegron: A Review in Overactive Bladder Syndrome.
    Deeks ED
    Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.